非维生素K拮抗剂口服抗凝药与华法林在老年亚洲房颤患者中的有效性与安全性比较:全国性队列研究
该研究利用台湾全民健康保险研究数据库,纳入2012至2015年64,169例≥65岁房颤患者,比较NOAC(达比加群、利伐沙班或阿哌沙班)与华法林的临床结局。总体NOAC组缺血性卒中(aHR 0.869;95%CI 0.812-0.931)、颅内出血(aHR 0.524;95%CI 0.456-0.601)、大出血(aHR 0.824;95%CI 0.776-0.875)、死亡(aHR 0.511;95%CI 0.491-0.532)及复合不良事件(aHR 0.646;95%CI 0.625-0.667)风险均显著低于华法林组。不同年龄分层存在治疗效应异质性,但≥90岁高龄人群结果仍 favoring NOAC。倾向匹配分析结果总体一致,且NOAC在老年人群中颅内出血和复合不良事件的绝对风险差异与降幅更明显。
要点
- ≥65岁亚洲房颤患者中,NOAC较华法林显著降低缺血性卒中风险(aHR 0.869;95%CI 0.812-0.931)。
- NOAC较华法林显著降低颅内出血风险(aHR 0.524;95%CI 0.456-0.601)和大出血风险(aHR 0.824;95%CI 0.776-0.875)。
- NOAC较华法林显著降低死亡风险(aHR 0.511;95%CI 0.491-0.532)和复合不良事件风险(aHR 0.646;95%CI 0.625-0.667)。
- 不同年龄分层存在治疗效应异质性,但≥90岁高龄人群结果仍 favoring NOAC。
- NOAC在老年人群中颅内出血和复合不良事件的绝对风险差异与降幅较华法林更明显。
适用人群与场景
- 2012至2015年台湾全民健康保险研究数据库中≥65岁房颤患者,至少接受一次NOAC(达比加群、利伐沙班或阿哌沙班)或华法林处方。
- 按年龄分层:65-74岁、75-89岁、≥90岁。
研究设计与关键结果
- 研究类型:全国性队列研究,样本量64,169例≥65岁房颤患者。
- 干预与对照:NOAC(达比加群、利伐沙班或阿哌沙班)vs 华法林。
- 主要终点:NOAC组较华法林组缺血性卒中aHR 0.869(95%CI 0.812-0.931)、颅内出血aHR 0.524(95%CI 0.456-0.601)、大出血aHR 0.824(95%CI 0.776-0.875)、死亡aHR 0.511(95%CI 0.491-0.532)、复合不良事件aHR 0.646(95%CI 0.625-0.667)均显著降低。
- 不同年龄分层存在治疗效应异质性,但≥90岁高龄人群结果仍 favoring NOAC。
- 倾向匹配分析结果总体一致;NOAC在老年人群中颅内出血和复合不良事件的绝对风险差异与降幅较华法林更明显。
证据类型、等级与局限
- 证据类型:全国性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在≥65岁亚洲房颤患者卒中预防中,NOAC较华法林与更低缺血性卒中、颅内出血、大出血、死亡及复合不良事件风险相关,≥90岁高龄人群仍 favoring NOAC。
- 不同年龄分层存在治疗效应异质性,临床决策需结合具体年龄层评估。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Stroke prevention in elderly patients with atrial fibrillation (AF) can be challenging, requiring a balance between thromboembolism prevention and serious bleeding. Comparisons of nonvitamin K antagonist oral anticoagulants (NOACs) and warfarin in older adults at different age strata (65-74, 75-89, and ≥ 90 years of age) in the daily practice have not been well described, particularly in Asians. We aimed to assess the clinical outcomes of NOACs compared with warfarin for stroke prevention in elderly patients with AF.
METHODS: From 2012 to 2015, 64,169 patients ≥ 65 years of age with AF who received at least one NOAC (dabigatran, rivaroxaban, or apixaban) or warfarin prescription were identified from the Taiwan National Health Insurance Research Database. The risks of ischemic stroke, intracranial hemorrhage (ICH), major bleeding, mortality, and composite adverse events were compared between NOACs and warfarin in all patients ≥ 65 years of age and, specifically, with different age strata (ie, 65-74, 75-89, ≥ 90 years).
RESULTS: Overall, NOACs were associated with a significantly lower risk of ischemic stroke (adjusted hazard ratio [aHR], 0.869; 95% CI, 0.812-0.931), ICH (aHR, 0.524; 95% CI, 0.456-0.601), major bleeding (aHR, 0.824; 95% CI, 0.776-0.875), mortality (aHR, 0.511; 95% CI, 0.491-0.532), and composite adverse events (aHR, 0.646; 95% CI, 0.625-0.667) than warfarin. There was heterogeneity in treatment effect for NOACs vs warfarin in different age strata, but the results still favored NOACs even among very older adults (≥ 90 years). The results were generally consistent with propensity matching analysis. The absolute risk difference and reductions in ICH and composite adverse events with NOAC use were even greater among older adults than warfarin.
CONCLUSIONS: Compared with warfarin, NOACs were associated with a significantly lower risk of adverse events, with heterogeneity in treatment effects among different age strata. Overall, the clear safety signal in favor of NOACs over warfarin was evident irrespective of age strata, being most marked in very older adults.
参考来源
- Chao TF, Chiang CE, Liao JN, et al. Comparing the Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants and Warfarin in Elderly Asian Patients With Atrial Fibrillation: A Nationwide Cohort Study. Chest. 2019. PMID: 31809694. doi:10.1016/j.chest.2019.11.025
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。